沛爾生技醫藥股份有限公司
沛爾生技醫藥股份有限公司為免疫細胞療法研發公司。專注於嵌合抗原受體 T 細胞（CAR-T）技術，主要開發針對 B 細胞淋巴瘤與實體腫瘤之新藥。公司具備符合標準之細胞製備廠與研發中心。公司成立於 2017 年，總部位於台灣台北。
該股 RSI(6) 為 58.0，處於中性區間，短線無明顯超買超賣訊號。股價站上5日、20日、60日、120日均線。KD 指標中性（K=67.8）；MACD 柱狀體為負值，空方動能持續。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-10 | +1 | 0 | +1 | +2 |
| 08-07 | -17 | 0 | 0 | -17 |
| 08-06 | +30 | 0 | -10 | +20 |
| 08-05 | +93 | 0 | -14 | +79 |
| 08-04 | +45 | 0 | -2 | +43 |
| 08-03 | +17 | 0 | -3 | +14 |
| 07-31 | -38 | 0 | 0 | -38 |
| 07-30 | -45 | 0 | -2 | -47 |
| 07-29 | +16 | 0 | +4 | +20 |
| 07-28 | +13 | 0 | +2 | +15 |
| 07-27 | +1 | 0 | 0 | +1 |
| 07-24 | 0 | 0 | +3 | +2 |
| 07-23 | +32 | 0 | 0 | +32 |
| 07-22 | +18 | 0 | 0 | +18 |
| 07-21 | -64 | 0 | -3 | -67 |
| 07-20 | +33 | 0 | -4 | +29 |
| 07-17 | +51 | 0 | +5 | +56 |
| 07-16 | +190 | 0 | -14 | +175 |
| 07-15 | +280 | 0 | +10 | +291 |
| 07-14 | +65 | 0 | -1 | +64 |
| 07-13 | -24 | 0 | -1 | -25 |
| 07-09 | -59 | 0 | -1 | -60 |
| 07-08 | +123 | 0 | 0 | +123 |
| 07-07 | +63 | 0 | 0 | +63 |
| 07-06 | -11 | 0 | +3 | -8 |
| 07-03 | +45 | 0 | +1 | +46 |
| 07-02 | -56 | 0 | 0 | -56 |
| 07-01 | +26 | 0 | -1 | +26 |
| 06-30 | +1 | 0 | -1 | 0 |
| 06-29 | +3 | 0 | 0 | +3 |
| 06-26 | 0 | 0 | -3 | -3 |
| 06-25 | -18 | 0 | +1 | -17 |
| 06-24 | -27 | 0 | 0 | -26 |
| 06-22 | -69 | 0 | +1 | -68 |
| 06-18 | +171 | 0 | -14 | +157 |
| 06-17 | +26 | 0 | +13 | +39 |
| 06-16 | +85 | 0 | 0 | +85 |
| 06-15 | +13 | 0 | 0 | +12 |
| 06-12 | +19 | 0 | +7 | +26 |
| 06-10 | +69 | 0 | 0 | +69 |
| 06-09 | +18 | 0 | -1 | +17 |
| 06-08 | +66 | 0 | 0 | +66 |
| 06-04 | -20 | 0 | -1 | -21 |
| 06-03 | -11 | 0 | 0 | -11 |
| 06-02 | -28 | 0 | 0 | -28 |
| 06-01 | -36 | 0 | -2 | -37 |
| 05-29 | -85 | 0 | -1 | -86 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/06 | 328 萬 | +21.7% | +50.2% |
| 2026/05 | 269 萬 | -9.4% | +18.8% |
| 2026/04 | 297 萬 | +21.1% | +107.9% |
| 2026/03 | 245 萬 | +24.5% | +74.5% |
| 2026/02 | 197 萬 | -0.4% | +61.2% |
| 2026/01 | 198 萬 | -14.6% | -78.3% |
| 2025/12 | 232 萬 | +36.9% | +26.4% |
| 2025/11 | 169 萬 | -21.4% | +8.0% |
| 2025/10 | 215 萬 | +14.1% | +53.5% |
| 2025/09 | 189 萬 | -23.1% | +8.4% |
| 2025/08 | 245 萬 | -24.6% | +63.4% |
| 2025/07 | 326 萬 | - | +87.6% |